Status:
COMPLETED
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
Lead Sponsor:
Nycomed
Conditions:
Sleep Disorders
Non-Erosive Reflux Disease
Eligibility:
All Genders
12+ years
Brief Summary
The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease). The prevalence...
Eligibility Criteria
Inclusion
- Main inclusion criteria:
- Outpatients with erosive gastro-esophageal reflux disease (eGERD) or non-erosive reflux disease (NERD)
- Main exclusion criteria:
- Criteria as defined in the respective Summary of Product Characteristics (Chapter 4.3)
Exclusion
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
1045 Patients enrolled
Trial Details
Trial ID
NCT00830115
Start Date
January 1 2009
End Date
June 1 2009
Last Update
May 8 2012
Active Locations (201)
Enter a location and click search to find clinical trials sorted by distance.
1
Nycomed Deutschland GmbH
Aachen, Germany, 52078
2
Nycomed Deutschland GmbH
Ahrensburg, Germany, 22926
3
Nycomed Deutschland GmbH
Altenburg, Germany, 04600
4
Nycomed Deutschland GmbH
Ansbach, Germany, 91522